Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability and PK of Single Rising Doses of BI 425809 in Healthy Japanese and Chinese Males
NCT02383888Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- May 2015
- Primary completion
- Aug 2015
- Modality
- Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of iclepertin in schizophrenia (4 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Number of Subjects With Drug-Related Adverse Events up to 11 days. Started May 2015; status: completed.
02
Drugs
iclepertin
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT02383888.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02383888.